According to a new report published by Allied Market Research, titled, " Cystic Fibrosis Therapeutics Market by Drug Class and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2018-2026," the global cystic fibrosis therapeutics market size is expected to reach $9,277 million by 2026, registering a CAGR of 9.2% from 2019 to 2026, in terms of value.
Cystic fibrosis is a hereditary disease that majorly affects the lungs and digestive system. In cystic fibrosis, the body produces thick and sticky mucus that may block the lungs and impede the pancreas. The disease can be lethal, and patients tend to have a shorter-than-normal life span. Further, the disease is so dangerous that all newborns in the U.S. are screened for CF. Moreover, there is no cure for cystic fibrosis, but taking proper nutrition and medications to thin excess mucus produced in lungs & kidney can help in increasing patient’s lifespan. In addition, treatment of cystic fibrosis includes the use of drugs such as Pulmozyme, Kalydeco, and others. These drugs can be administered to the patient by different routes such as oral and by inhalation.
Rise in incidence of cystic fibrosis across the globe and increase in medications against cystic fibrosis are the major factors driving the market growth. Moreover, rise in R&D investments toward the development of drugs to treat cystic fibrosis propels the cystic fibrosis therapeutics market growth. However, high cost of the cystic fibrosis treatment and introduction of generic drugs hinder the growth of the market. Moreover, development of the healthcare industry in the developing economies are expected to create lucrative opportunities in the near future. Furthermore, rise in prevalence of cystic fibrosis has generated need for newer and advanced therapeutics for its treatment. Hence, this has led to increase in number of pipeline drugs in the market, which is expected to provide remunerative opportunities for market expansion during the forecast period.
By cystic fibrosis therapeutics market analysis, based on drug class, the CFTR modulators segment dominated the market in 2018 and is anticipated to continue its dominance during the forecast period. This is attributed to increased usage of these drugs for the treatment of cystic fibrosis. Further, these drugs target the production and function of the mutant CFTR protein. In addition, the CFTR protein regulates the flow of water and chloride in and out of cells lining the lungs and other organs. These drugs are being considered as potent therapeutics for the treatment of the disease. The three major types of modulators are potentiators, correctors, and amplifiers.
By route of administration, oral segment accounted for the majority of market share in 2018, owing to increased formulation of cystic fibrosis therapeutics in oral form. Further, there are currently three CFTR modulator drugs approved by the U.S. FDA, all of which are oral tablets. These include ivacaftor (kalydeco), orkambi and symdeko. As per the current cystic fibrosis therapeutics market trend, the oral route of administration is estimated to grow at the fastest growth rate during the forecast period.
Key Findings of the Cystic Fibrosis Therapeutics Market:
- By drug class, the CFTR segment accounted for the highest market share of 65% in 2018 and is anticipated to grow at the fastest rate during the forecast period.
- By region, Europe was the major shareholder and accounted for the highest share of 33% in 2018.
- By route of administration, oral segment is expected to grow at a CAGR of 9.9% during the forecast period.
- North America is anticipated to grow at the fastest CAGR of 9.8% during the forecast period.
Key players operating in cystic fibrosis therapeutic markets are Genentech, Inc., Novartis AG, Gilead Sciences, Inc., Vertex Pharmaceuticals Incorporated, AbbVie Inc., GlaxoSmithKline Plc., Johnson & Johnson, Allergan plc, Pharmaxis Ltd., and Mylan N.V.